On 21st July 2022, Pacific Edge announced that it had substantially completed a commercial agreement with Te Whatu Ora – Southern for the use of its Cxbladder genomic biomarker tests.
The contract is yet to be signed and is currently being reviewed by Te Whatu Ora – Southern Management Team, following which it will enter an approvals cycle.
See more